• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cybin Inc.

    11/6/25 4:40:37 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    6-K 1 cybininc-form6xk11x06x2025.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of November, 2025.
    Commission File Number: 001-40673


    Cybin Inc.
    (Exact Name of Registrant as Specified in Charter)

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F □ Form 40-F ⊠







    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    CYBIN INC.
    (Registrant)
     
    Date:November 6, 2025By:
    /s/ Greg Cavers    
    Name:Greg Cavers
    Title:Chief Financial Officer





    EXHIBIT INDEX

    99.1
    News Release dated November 6, 2025

    Get the next $CYBN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Cybin with a new price target

    Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

    3/13/25 7:34:44 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Cybin with a new price target

    HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

    11/22/21 6:24:49 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin downgraded by Maxim Group

    Maxim Group downgraded Cybin from Buy to Hold

    11/19/21 8:09:52 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    - Closed registered direct offering for aggregate gross proceeds of US$175 million (the "Registered Direct Offering") led by a syndicate of prominent biopharmaceutical institutional investors - - On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder ("GAD") in Q1 20261 - - Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder ("MDD") - -The Company's cash position as at September 30, 2025 after giving effect to the net proceeds of the Registered Direct Offering is US$248 million - - Repayment of outstanding convertible debentures to High Trail Special Situations LLC an

    11/13/25 7:20:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Participate in the Jefferies Global Healthcare Conference in London

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that George Tziras, Cybin's Chief Business Officer, will present at the Jefferies Global Healthcare Conference, taking place November 17-20, 2025, in London, UK. The presentation will be webcast live on Monday, November 17, 2025, at 12:30 p.m. GMT (7:30 a.m. ET). To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Even

    11/12/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    SEC Filings

    View All

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    11/13/25 7:24:53 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    11/12/25 11:10:16 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Cybin Inc.

    SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

    11/7/25 4:38:30 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Leadership Updates

    Live Leadership Updates

    View All

    Cybin Announces Results of Annual Meeting of Shareholders

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the "Meeting"). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:

    8/18/25 5:30:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

    - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

    4/23/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

    - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

    10/1/24 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cybin Inc.

    SC 13G - CYBIN INC. (0001833141) (Subject)

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 6:55:13 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Financials

    Live finance-specific insights

    View All

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

    - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

    11/18/24 7:00:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

    - Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

    11/14/24 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care